-+ 0.00%
-+ 0.00%
-+ 0.00%

Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice

Barchart·04/07/2025 23:36:19
Listen to the news
As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.